Abstract:# 464 STAT4 deficiency exacerbates atherosclerosis by promoting mobilization of myeloid cells, polarization of M1 macrophages and formation of foam cells {#article-title-2}Background: Atherosclerosis (AS) is a chronic inflammatory disease of large and medium size vessels. Signal transducer and activator of transcription 4 (STAT4) has been reported to regulated the proliferation and differentiation of myeloid cells. However, the role of STAT4 in atherosclerotic progression is not well defined.Methods: We constructed APOE/STAT4 double knock out (DKO) mice via hybridization of ApoE-/- and STAT4-/- mice. 10 ApoE-/- mice (control) and 10 DKO mice were challenged with high-fat diet for 12 weeks. The extent of AS was determined by oil-red staining and HE staining. Plasma cholesterol, triglyceride and cytokines were assessed by ELISA. Changes in subsets of immune cells were evaluated by flow cytometry. Microarray analysis was applied to detect gene expressions while Western blot was used to assess protein levels.Results: Genetic deletion of STAT4 significantly exacerbated AS as evidenced by markedly increased oil-red-positive lipid-rich lesion in DKO mice accompanied by reduction of collagen fiber and increase of necrotic core lesion in plaques. Higher level of TC, TG and LDL-C in the serum and more abdominal fat were detected in DKO mice. Increased percentage of CD11b+Gr-1+ myeloid cells and Ly6Chigh M1 macrophage in peripheral blood, bone marrow and spleen of DKO mice suggested that STAT4 signal may play a critical role in regulating the proliferation and mobilization of myeloid cells and polarization of macrophages. To further explore the impact of STAT4 deficiency in myeloid cells, we isolated CD11b+ myeloid cells from bone marrows of ApoE-/- and DKO mice and incubated them with GM-CSF (60ng/ml) plus ox-LDL (60ug/ml). Enhanced differentiation of CD11b+Ly6Chigh macrophage and increase formation of foam cells were detected in DKO group. IFN-γ in the supernatant increased while IL-10 decreased in DKO group, indicating enhanced polarization of M1 macrophage from CD11b+ cells of DKO mice. Meanwhile, microarray data demonstrated that STAT4 KO increased expression levels of M1-related genes such as inducible nitric oxide synthase (iNos). Mechanistically, STAT4 deficiency significantly promoted the formation of foam cells by inhibiting of phosphatidylinositol-3 kinase/ serine-threonine kinases (PI3K/AKT) signal and consequently up-regulating of the expression of acyl coenzyme A: cholesterol acyltransferase-1 (ACAT-1), an enzyme that esterifies cholesterol and promotes its storage in macrophages.Conclusions: Our studies identified STAT4 as a regulator of the proliferation and differentiation of myeloid cells and atherogenesis. PI3K/AKT/ACAT-1 signaling was the molecular mechanisms of STAT4 functioning in the process. These findings points towards the development of STAT4 as a novel pharmacotherapeutic target for the treatment of atherosclerotic diseases and ApoE/STAT4 DKO mice with hyperlipidemia and hyper-inflammation as a novel mouse model more susceptible to atherosclerosis for future study.# 465 Effects of DPP4 inhibition on cardiac regeneration and macrophage balance in a mouse model of HHT-1 {#article-title-3}Background: Hereditary Hemorrhagic Telangiectasia type 1 (HHT-1) is a genetic dominant vascular disorder caused by haploinsufficiency of the TGFβ co-receptor Endoglin. Although the pathology of HHT-1 suggests that mainly vascular endothelial cells are involved, we have previously shown dysfunctional homing of mononuclear cells (MNC) towards the infarcted myocardium (MI). This is most likely due to enhanced expression of dipeptidyl peptidase-4 (DPP4). DPP4 inactivates SDF-1α, thereby inhibiting recruitment of CXCR4 expressing cells.Purpose: Our aim is to increase homing of the HHT-1 MNC and improve cardiac recovery and function in HHT-1 mice following MI, by inhibition of DPP4 activity.Methods: MI was induced in wildtype (WT) and endoglin heterozygous (eng+/-; as a model of HHT-1) mice by ligation of the left anterior descending (LAD) coronary artery, followed by 5 days of daily treatment with the DPP4 inhibitor Diprotin A (2.5mg/kg/day). The infarcted hearts were assessed at day 4 and at day 14 post MI.Results: DPP4 inhibition restored the number of MNC present in the infarcted hearts and significantly reduced infarct size (eng+/- 46.60±9.33% vs. eng+/- treated 27.02±3.04%, P=0.03), as measured by myocardial collagen formation. Analysis of cardiac function using ultrasound demonstrated that treatment of WT mice improved ejection fraction, however showed a slightly deteriorating effect in the eng+/- animals. Investigating the infarct borderzone, the number of capillaries increased (eng+/- 61.63±1.43 vs. eng+/- treated 74.30±1.74, P=0.001) while the number of arteries decreased (eng+/- 11.88±0.63 vs. eng+/- treated 6.38±0.97, P=0.003), suggesting that angiogenesis is upregulated, though the maturation of the new vessels is still impaired. Furthermore at day 4 post-MI, during the peak of inflammatory cell influx, Eng+/- mice show a significant decrease (WT 29.88±1.52 vs. eng+/- 12.34±1.64, Pu003c0.0001) of regenerative M2 macrophages in the heart compared to WT mice which continued to day 14 post-MI, together with an overall increase in macrophage presence. DPP4 inhibition corrected the M2 levels at day 4 and even at 14 days post MI the increased M2 levels had persisted.Conclusions: The findings show we can restore impaired MNC homing in eng+/- mice by systemic DPP4 inhibition, though we see no effect on cardiac ejection fraction, cardiac repair is improved as demonstrated by a decreased fibrotic response, resulting in a decreased infarct size. Furthermore our results suggest eng+/- mice have a defect in macrophage differentiation and function. We observe that inhibition of DPP4 results in an increase in angiogenesis and rescues the amount of M2 macrophages to wildtype levels.# 466 Myeloid cell regulation by CD200 signalling in atherosclerosis {#article-title-4}Background: Atherosclerosis, the major risk factor for cardiovascular disease and the leading cause of death worldwide, is a multifactorial chronic inflammatory disease. CD200 is reported to be an endogenous myeloid suppressor. Deletion of CD200 in vivo increases myeloid cell numbers and activation resulting in enhanced susceptibility to autoimmune diseases and infection. However, the importance of CD200 in atherosclerosis development is still unknown.Methods and Results: To understand the role of CD200 signalling, both the effect of CD200 deletion and provision were assessed in a murine model of atherosclerosis. Firstly, CD200-deficient (CD200-/-) mice were crossed with apolipoprotein E deficient (ApoE-/-) mice. CD200 deficiency accelerates advanced atherosclerotic lesion formation in the aortic roots, as shown by the morphometric measurement of aortic root atherosclerotic lesion development. Moreover, the leukocyte content of various tissues was assessed by flow cytometry. APOE-/-CD200-/- mice exhibit significant increase in specific myeloid cell populations in spleen, blood and aorta. Secondly, the role of CD200R ligation has been examined in a murine model of carotid injury. ApoE-/-mice underwent surgery for placement of a perivascular collar and were treated with 10mg/kg of a CD200-Fc fusion protein. Three weeks post injury, carotid arteries were removed and neointima formation was assessed. CD200-Fc fusion protein treatment attenuated neointima development. Interestingly, CD200-Fc fusion protein affects macrophage accumulation and polarization.Conclusions: Our data indicate that CD200 is an important modulator of myeloid cell function and phenotype in atherosclerosis and suggest that targeting the CD200-CD200R pathway holds promise as a potential therapeutic strategy in atherosclerosis.

Abstract:HomeCirculationVol. 137, No. 7Proefferocytic Therapy Promotes Transforming Growth Factor-β Signaling and Prevents Aneurysm Formation Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBProefferocytic Therapy Promotes Transforming Growth Factor-β Signaling and Prevents Aneurysm Formation Yoko Kojima, MD, PhD, Norna Werner, MD, Jianqin Ye, MD, PhD, Vivek Nanda, PhD, Noah Tsao, Ying Wang, PhD, Alyssa M. Flores, BS, Clint L. Miller, PhD, Irving Weissman, MD, Hongping Deng, MD, PhD, Baohui Xu, MD, PhD, Ronald L. Dalman, MD, Suzanne M. Eken, MD, PhD, Jaroslav Pelisek, PhD, Yuhuang Li, MD, PhD, Lars Maegdefessel, MD, PhD and Nicholas J. Leeper, MD Yoko KojimaYoko Kojima Department of Surgery, Division of Vascular Surgery (Y.K., N.W., J.Y., V.N., N.T., Y.W., A.M.F., H.D., B.X., R.L.D., N.J.L.) , Norna WernerNorna Werner Department of Surgery, Division of Vascular Surgery (Y.K., N.W., J.Y., V.N., N.T., Y.W., A.M.F., H.D., B.X., R.L.D., N.J.L.) , Jianqin YeJianqin Ye Department of Surgery, Division of Vascular Surgery (Y.K., N.W., J.Y., V.N., N.T., Y.W., A.M.F., H.D., B.X., R.L.D., N.J.L.) , Vivek NandaVivek Nanda Department of Surgery, Division of Vascular Surgery (Y.K., N.W., J.Y., V.N., N.T., Y.W., A.M.F., H.D., B.X., R.L.D., N.J.L.) , Noah TsaoNoah Tsao Department of Surgery, Division of Vascular Surgery (Y.K., N.W., J.Y., V.N., N.T., Y.W., A.M.F., H.D., B.X., R.L.D., N.J.L.) , Ying WangYing Wang Department of Surgery, Division of Vascular Surgery (Y.K., N.W., J.Y., V.N., N.T., Y.W., A.M.F., H.D., B.X., R.L.D., N.J.L.) , Alyssa M. FloresAlyssa M. Flores Department of Surgery, Division of Vascular Surgery (Y.K., N.W., J.Y., V.N., N.T., Y.W., A.M.F., H.D., B.X., R.L.D., N.J.L.) , Clint L. MillerClint L. Miller Department of Medicine, Division of Cardiovascular Medicine (C.L.M., N.J.L.) , Irving WeissmanIrving Weissman Institute for Stem Cell Biology and Regenerative Medicine (I.W.) , Hongping DengHongping Deng Department of Surgery, Division of Vascular Surgery (Y.K., N.W., J.Y., V.N., N.T., Y.W., A.M.F., H.D., B.X., R.L.D., N.J.L.) , Baohui XuBaohui Xu Department of Surgery, Division of Vascular Surgery (Y.K., N.W., J.Y., V.N., N.T., Y.W., A.M.F., H.D., B.X., R.L.D., N.J.L.) , Ronald L. DalmanRonald L. Dalman Department of Surgery, Division of Vascular Surgery (Y.K., N.W., J.Y., V.N., N.T., Y.W., A.M.F., H.D., B.X., R.L.D., N.J.L.) , Suzanne M. EkenSuzanne M. Eken Stanford University School of Medicine, CA. Department of Medicine, Karolinska Institute, Stockholm, Sweden (S.M.E., L.M.) , Jaroslav PelisekJaroslav Pelisek Department of Vascular and Endovascular Surgery, Klinikum Rechts der Isar, Technical University Munich and German Center for Cardiovascular Research Partner Site Munich, Munich, Germany (J.P., Y.L., L.M.) , Yuhuang LiYuhuang Li Department of Vascular and Endovascular Surgery, Klinikum Rechts der Isar, Technical University Munich and German Center for Cardiovascular Research Partner Site Munich, Munich, Germany (J.P., Y.L., L.M.) , Lars MaegdefesselLars Maegdefessel Stanford University School of Medicine, CA. Department of Medicine, Karolinska Institute, Stockholm, Sweden (S.M.E., L.M.) Department of Vascular and Endovascular Surgery, Klinikum Rechts der Isar, Technical University Munich and German Center for Cardiovascular Research Partner Site Munich, Munich, Germany (J.P., Y.L., L.M.) and Nicholas J. LeeperNicholas J. Leeper Department of Surgery, Division of Vascular Surgery (Y.K., N.W., J.Y., V.N., N.T., Y.W., A.M.F., H.D., B.X., R.L.D., N.J.L.) Department of Medicine, Division of Cardiovascular Medicine (C.L.M., N.J.L.) Originally published13 Feb 2018https://doi.org/10.1161/CIRCULATIONAHA.117.030389Circulation. 2018;137:750–753"Efferocytosis" (Greek: to carry the dead to the grave) is the term used to describe the phagocytic removal of apoptotic cells. Impaired efferocytosis was recently shown to be causal for atherosclerosis, where an imbalance in so-called eat me ligands allows uncleared cells to accumulate in the plaque and potentiate lesion expansion. We showed that this defect could be reversed with proefferocytic therapies, which led to marked reductions in disease burden.1 The majority of the antiatherosclerotic benefit appeared to occur via specific targeting of apoptotic debris and regression of the necrotic core.2It is important to note, however, that the consequences of efferocytic signaling extend beyond the simple engulfment of diseased cells. For example, macrophages that have successfully phagocytosed an apoptotic body are known to secrete a number of antiinflammatory factors.3 Some of these could theoretically influence vessel integrity, medial degeneration, and macrophage recruitment. Accordingly, we hypothesized that efferocytosis could have relevance to vascular disorders other than atherosclerosis, including those not driven by growth of the necrotic core, such as abdominal aortic aneurysm (AAA). Ethics and Institutional Review Board approvals were provided by Stanford University (protocol 27279), the Karolinska Institute (protocols N48/16 and N30/16), and the Munich Vascular Biobank (protocol 2799/10); and informed consent was received from all participants.To test this hypothesis, we performed genomic profiling in aortic samples harvested from mice and humans with AAA disease.4 In both species, the key don't eat me molecule, CD47, was found to be upregulated in aneurysmal tissue compared with control (Figure, A). These data suggest that a defect in programmed cell removal may contribute to the high prevalence of apoptotic cells observed in AAA disease. We then assessed whether restoration of efferocytosis could ameliorate vascular degeneration in 2 murine models of AAA disease, including the apoE−/−/AngII model and the porcine pancreatic elastase model (as described in detail in4). In each case, mice treated with proefferocytic anti-CD47 antibodies developed significantly smaller aortic diameters relative to IgG control (Figure, B).Download figureDownload PowerPointFigure. The "don't eat me" molecule, CD47, is a new translational target for AAA.A, mRNA analysis revealed that CD47 is upregulated in murine (2.4x, left) and human (6.5x; middle) AAA samples, relative to control aortae (N=5–6/condition). Immunohistochemical staining (right) confirmed the upregulation of CD47 on inflammatory cells in the media of human AAA samples (Abcam B6H12.2). B, apoE−/− mice infused with 1000 ng/kg/min of AngII via minipumps were protected from AAA disease when treated with 200 µg of anti-CD47 Ab (MIAP410, BioXcell) QOD (N=15–16/condition; top). Similar findings were observed for C57BL/6 mice in the elastase model, where serial ultrasounds confirmed a protective effect at the terminal end point (MOPC-21, BioXcell, N=9/condition; bottom). C, Immunoflourescence staining for phosphorylated SHP1 (CD47's downstream effector molecule) was significantly reduced in lesional macrophages in mice receiving therapy (green; Abcam ab131500). Colocalization studies revealed that anti-CD47 antibody reduced the ratio of free apoptotic bodies (AB, indicated by TUNEL staining; Roche Cell Death Detection Kit) to those colocalizing with macrophages (indicated by Mac-2 staining; BD-550292), indicative of an increase in the phagocytic index (stars indicate free, arrows indicate associated AB). The overall burden of AB and adventitial macrophages was also reduced (P<0.01 and 0.05, respectively). D, Medial staining for the key antianeurysmal factors, TGFβ (red, Proteintech #18978-1) and SMAD-3 (green, Proteintech #25494-1), were significantly increased by proefferocytic anti-CD47 Ab therapy. E, CD47 and TGFβ are inversely correlated in human AAA samples. AAA indicates abdominal aortic aneurysm; QOD, every other day; and TGFβ, transforming growth factor-β. *P<0.05; **P<0.03; ***P<0.01 via 2-tailed Student t tests. Error bars represent the standard error of mean.We next evaluated the mechanism by which this therapy prevented aneurysm disease. Although anti-CD47 Ab had no effect on macrophage polarization, endothelial function, TIMP activity, or metalloproteinase elaboration (not shown), we did observe a significant reduction in vascular phospho-SHP1 staining (a factor known to inhibit efferocytosis when phosphorylated1). This change was associated with a reduction in free apoptotic cells and adventitial macrophages, along with an increase in the colocalization of the remaining TUNEL+ and Mac-2+ cells (Figure, C). These data indicate an improvement in the phagocytic index in the vessel wall1 and suggest that diseased tissues were cleared before they could undergo secondary necrosis (which promotes recruitment of additional inflammatory cells). In keeping with prior reports,3 this augmentation in efferocytosis was associated with increased staining for the potent antianeurysmal cytokine, transforming growth factor-β,5 as well as its downstream signaling factor, SMAD3 (Figure, D). In support of a mechanistic association, CD47 and transforming growth factor-β were found to be anticorrelated in human AAA samples (Figure, E).To date, no medical therapy has been conclusively shown to prevent AAA disease, and this highly morbid condition continues to affect >10% of men >75 years of age.5 This study is the first to associate disease pathogenesis with a defect in efferocytosis and suggests that restorative therapy could promote fibrotic processes, which may stabilize the enlarging aorta. Prophagocytic antibodies are currently being investigated in human oncology trials for cancers that upregulate don't eat me molecules to evade tumoricidal macrophages (ClinicalTrials.gov. Unique identifier: NCT02216409). Assuming they prove safe and effective, efferocytosis-stimulating therapies could represent a new nonsurgical approach for aortic disease.Yoko Kojima, MD, PhDNorna Werner, MDJianqin Ye, MD, PhDVivek Nanda, PhDNoah TsaoYing Wang, PhDAlyssa M. Flores, BSClint L. Miller, PhDIrving Weissman, MDHongping Deng, MD, PhDBaohui Xu, MD, PhDRonald L. Dalman, MDSuzanne M. Eken, MD, PhDJaroslav Pelisek, PhDYuhuang Li, MD, PhDLars Maegdefessel, MD, PhDNicholas J. Leeper, MDSources of FundingThis study was supported by the National Institutes of Health (R01HL12522401 and R01HL12337001 to NJL).DisclosuresDrs Leeper and Weissman are cofounders and hold equity interest in 47 Incorporated.Footnoteshttp://circ.ahajournals.orgThe data, analytic methods, and study materials will be maintained by the corresponding author and made available to other researchers upon request.Nicholas J. Leeper, MD, Divisions of Vascular Surgery and Cardiovascular Medicine, Stanford University, 300 Pasteur Drive, Room H3638, Stanford, CA 94305. E-mail [email protected]References1. Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusis AJ, Miller CL, Direnzo D, Nanda V, Ye J, Connolly AJ, Schadt EE, Quertermous T, Betancur P, Maegdefessel L, Matic LP, Hedin U, Weissman IL, Leeper NJ. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.Nature. 2016; 536:86–90. doi: 10.1038/nature18935.CrossrefMedlineGoogle Scholar2. Kojima Y, Weissman IL, Leeper NJ. The role of efferocytosis in atherosclerosis.Circulation. 2017; 135:476–489. doi: 10.1161/CIRCULATIONAHA.116.025684.LinkGoogle Scholar3. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF.J Clin Invest. 1998; 101:890–898. doi: 10.1172/JCI1112.CrossrefMedlineGoogle Scholar4. Maegdefessel L, Spin JM, Raaz U, Eken SM, Toh R, Azuma J, Adam M, Nakagami F, Nagakami F, Heymann HM, Chernogubova E, Chernugobova E, Jin H, Roy J, Hultgren R, Caidahl K, Schrepfer S, Hamsten A, Eriksson P, McConnell MV, Dalman RL, Tsao PS. miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development.Nat Commun. 2014; 5:5214. doi: 10.1038/ncomms6214.CrossrefMedlineGoogle Scholar5. Wang Y, Krishna S, Walker PJ, Norman P, Golledge J. Transforming growth factor-beta and abdominal aortic aneurysms.Cardiovas Pathol. 2013; 22:126–132.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByJarr K, Kojima Y, Weissman I and Leeper N (2022) 2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis, Arteriosclerosis, Thrombosis, and Vascular Biology, 42:6, (e145-e154), Online publication date: 1-Jun-2022. Elder C, Filiberto A, Su G, Ladd Z, Leroy V, Pruitt E, Lu G, Jiang Z, Sharma A and Upchurch G (2021) Maresin 1 activates LGR6 signaling to inhibit smooth muscle cell activation and attenuate murine abdominal aortic aneurysm formation, The FASEB Journal, 10.1096/fj.202100484R, 35:8, Online publication date: 1-Aug-2021. Tang Y, Fan W, Zou B, Yan W, Hou Y, Kwabena Agyare O, Jiang Z and Qu S (2021) TGF-β signaling and microRNA cross-talk regulates abdominal aortic aneurysm progression, Clinica Chimica Acta, 10.1016/j.cca.2020.12.031, 515, (90-95), Online publication date: 1-Apr-2021. Khoury M, Yang H and Liu B (2020) Macrophage Biology in Cardiovascular Diseases, Arteriosclerosis, Thrombosis, and Vascular Biology, 41:2, (e77-e81), Online publication date: 1-Feb-2021. Song P, Zhao Q and Zou M (2020) Targeting senescent cells to attenuate cardiovascular disease progression, Ageing Research Reviews, 10.1016/j.arr.2020.101072, 60, (101072), Online publication date: 1-Jul-2020. Liu B, Granville D, Golledge J and Kassiri Z (2020) Pathogenic mechanisms and the potential of drug therapies for aortic aneurysm, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00621.2019, 318:3, (H652-H670), Online publication date: 1-Mar-2020. IJpma , te Riet , van de Luijtgaarden , van Heijningen , Burger , Majoor-Krakauer , Rouwet , Essers , Verhagen and van der Pluijm (2019) Inflammation and TGF-β Signaling Differ between Abdominal Aneurysms and Occlusive Disease, Journal of Cardiovascular Development and Disease, 10.3390/jcdd6040038, 6:4, (38) Wang Y, Nanda V and Leeper N (2019) Clonal Smooth Muscle Cell Expansion, Autophagy, and Vascular Integrity in Aortic Aneurysm Disease, Arteriosclerosis, Thrombosis, and Vascular Biology, 39:6, (982-983), Online publication date: 1-Jun-2019. Golledge J (2018) Abdominal aortic aneurysm: update on pathogenesis and medical treatments, Nature Reviews Cardiology, 10.1038/s41569-018-0114-9, 16:4, (225-242), Online publication date: 1-Apr-2019. February 13, 2018Vol 137, Issue 7 Advertisement Article InformationMetrics © 2018 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.117.030389PMID: 29440201 Originally publishedFebruary 13, 2018 KeywordsefferocytosisTGFβmacrophagevascular biologyaneurysmphagocytosisPDF download Advertisement SubjectsAneurysmVascular Biology

Macrophage-restricted Tyrosine Phosphatase SHP2 is a Novel Anti-Atherosclerotic Regulator

Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis.

Role of Dysregulated Macrophage Subpopulation Ratios and Functional Changes in the Development of Coronary Atherosclerosis.

Abstract 14122: Myeloid Cell Mpges-1 Depletion Attenuates Mortality after Myocardial Infarction in Mice

Myeloid Cell PKM2 Deletion Enhances Efferocytosis and Reduces Atherosclerosis

Macrophage-derived Myeloid Differentiation Protein 2 Plays an Essential Role in Ox-Ldl-induced Inflammation and Atherosclerosis

Inflammatory Crosstalk Impairs Phagocytic Receptors and Aggravates Atherosclerosis in Clonal Hematopoiesis in Mice

Deleting interleukin-10 from myeloid cells exacerbates atherosclerosis in Apoe−/− mice

CD147 Sparks Atherosclerosis by Driving M1 Phenotype and Impairing Efferocytosis

Impaired Autophagy in CD11b+ Dendritic Cells Expands CD4+ Regulatory T Cells and Limits Atherosclerosis in Mice

Myeloid Cell Mpges-1 Deletion Attenuates Mortality Without Affecting Remodeling after Acute Myocardial Infarction in Mice

MPS 11-02 Genetic Deletion of Chemokine Receptor Ccr6 Decreases Atherogenesis in ApoE-deficient Mice Through Mir-27B by Targeting Naa15

Macrophages overexpressing interleukin-10 target and prevent atherosclerosis: regression of plaque formation and reduction in necrotic core

Gsα Regulates Macrophage Foam Cell Formation During Atherosclerosis

Proefferocytic Therapy Promotes Transforming Growth Factor-β Signaling and Prevents Aneurysm Formation

Myeloid Deletion of α1AMPK Exacerbates Atherosclerosis in LDL Receptor Knockout (LDLRKO) Mice

1800-LB: Reprogramming of Macrophage Metabolism by Pyruvate Dehydrogenase Attenuates Atherosclerosis through Mitigation of iNOS-Induced Foam Cell Formation

Expression of Human Tissue Factor Pathway Inhibitor on Vascular Smooth Muscle Cells Inhibits Secretion of Macrophage Migration Inhibitory Factor and Attenuates Atherosclerosis in ApoE −/− Mice

Abstract 2067: Myeloid Cell Lgr4 Contributes to Atherosclerotic Lesion Formation

Abstract 16746: Novel Role of Endothelial CD45 in Regulating Endothelial-to-Mesenchymal Transition (endmt) in Atherosclerosis